Citi Starts Prothena Corp (PRTA) at Buy

Go back to Citi Starts Prothena Corp (PRTA) at Buy

Prothena (PRTA) Does First Patient in PRX002 Phase 1

April 8, 2014 4:42 PM EDT

Prothena Corporation plc (Nasdaq: PRTA) announced the successful start of a Phase 1 clinical trial of its therapeutic monoclonal antibody candidate, PRX002, for the treatment of Parkinson's disease. Prothena has earned a $15 million milestone payment from Roche related to the initiation of... More